Trial · NCT00459108
Results by group85
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 85
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Response Rate (Complete and Partial Response) | Oral Dasatinib | 0 | percentage of responding patients | ||
| Four Month Progression-free Survival (PFS) | Oral Dasatinib | 40 | 95% Confidence Interval 21 to 58 | percentage of participants | |
| Median Progression-free Survival | Oral Dasatinib | 3.7 | 95% Confidence Interval 1.8 to 6.4 | Months | |
| Overall Survival | Oral Dasatinib | 7.5 | 95% Confidence Interval 2.9 to 13.6 | Months | |
| Safety and Tolerability | Oral Dasatinib | Grade 3 : AST, SGOT | 2 | participants | |
| Safety and Tolerability | Oral Dasatinib | Grade 3 : Anorexia | 2 | participants | |
| Safety and Tolerability | Oral Dasatinib | Grade 3 : Sudden death | 0 | participants | |
| Safety and Tolerability | Oral Dasatinib | Grade 3 : Dehydration | 2 | participants | |
| Safety and Tolerability | Oral Dasatinib | Grade 3 : Diarrhea | 1 | participants | |
| Safety and Tolerability | Oral Dasatinib | Grade 3 : Dizziness | 0 | participants | |
| Safety and Tolerability | Oral Dasatinib | Grade 3 : Edema:head and neck | 1 | participants | |
| Safety and Tolerability | Oral Dasatinib | Grade 3 : Fatigue (asthenia, lethargy, malaise) | 8 | participants | |
| Safety and Tolerability | Oral Dasatinib | Grade 3 : Glucose, serum-high (hyperglycemia) | 1 | participants | |
| Safety and Tolerability | Oral Dasatinib | Grade 3 : Hemoglobin | 2 | participants | |
| Safety and Tolerability | Oral Dasatinib | Grade 3 : Hemorrhage, GI - Colon | 1 | participants | |
| Safety and Tolerability | Oral Dasatinib | Grade 3 : Hemorrhage, GI - Stomach | 1 | participants | |
| Safety and Tolerability | Oral Dasatinib | Grade 3 : Infection with normal ANC | 1 | participants | |
| Safety and Tolerability | Oral Dasatinib | Grade 3 : Leukocytes (total WBC) | 1 | participants | |
| Safety and Tolerability | Oral Dasatinib | Grade 3 : Lymphopenia | 2 | participants | |
| Safety and Tolerability | Oral Dasatinib | Grade 3 : Nausea | 3 | participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00459108/results